Birdwatch Note
2023-05-18 12:47:58 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
China did not reject the use of any mRNA vaccine. China has approved its first domestically developed mRNA vaccine against COVID-19 - a major achievement in a country that has declined to use foreign coronavirus shots to support domestic research. https://healthtimes.com.au/hub/covid-19/74/news/aap/china-approves-its-first-mrna-covid19-vaccine/7803/
Written by 11BD4779EEDEF6AD0A8B9909631A879F67A440041395BBCD87190183433B5876
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1658937850941919232
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1659179018917396480
- noteId - 1659179018917396480
- participantId -
- noteAuthorParticipantId - 11BD4779EEDEF6AD0A8B9909631A879F67A440041395BBCD87190183433B5876 Participant Details
- createdAtMillis - 1684414078823
- tweetId - 1658937850941919232
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- China did not reject the use of any mRNA vaccine. China has approved its first domestically developed mRNA vaccine against COVID-19 - a major achievement in a country that has declined to use foreign coronavirus shots to support domestic research. https://healthtimes.com.au/hub/covid-19/74/news/aap/china-approves-its-first-mrna-covid19-vaccine/7803/
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-05-18 12:47:58 UTC (1684414078823) |
2023-05-19 01:09:46 UTC (1684458586968) |
CURRENTLY_RATED_HELPFUL | 2023-05-31 02:39:52 UTC (1685500792003) |
CURRENTLY_RATED_HELPFUL | 2023-05-19 01:09:46 UTC (1684458586968) |
CURRENTLY_RATED_HELPFUL | |
2023-05-18 12:47:58 UTC (1684414078823) |
2023-05-19 01:09:46 UTC (1684458586968) |
CURRENTLY_RATED_HELPFUL | 2023-05-19 02:11:50 UTC (1684462310344) |
CURRENTLY_RATED_HELPFUL | 2023-05-19 01:09:46 UTC (1684458586968) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
rated at | rated by | |
2023-05-18 19:23:57 -0500 | Rating Details | |
2023-05-18 19:15:13 -0500 | Rating Details | |
2023-05-18 19:03:51 -0500 | Rating Details | |
2023-05-18 18:55:55 -0500 | Rating Details | |
2023-05-18 18:55:41 -0500 | Rating Details | |
2023-05-18 18:49:15 -0500 | Rating Details | |
2023-05-18 18:40:27 -0500 | Rating Details | |
2023-05-18 18:33:24 -0500 | Rating Details | |
2023-05-18 18:32:59 -0500 | Rating Details | |
2023-05-18 18:30:57 -0500 | Rating Details | |
2023-05-18 18:30:08 -0500 | Rating Details | |
2023-05-18 18:27:18 -0500 | Rating Details | |
2023-05-18 18:25:21 -0500 | Rating Details | |
2023-05-18 18:24:06 -0500 | Rating Details | |
2023-05-18 18:19:40 -0500 | Rating Details | |
2023-05-18 18:19:31 -0500 | Rating Details | |
2023-05-18 18:18:09 -0500 | Rating Details | |
2023-05-18 18:17:57 -0500 | Rating Details | |
2023-05-18 18:15:27 -0500 | Rating Details | |
2023-05-18 18:10:49 -0500 | Rating Details | |
2023-05-18 18:10:17 -0500 | Rating Details | |
2023-05-18 17:48:09 -0500 | Rating Details | |
2023-05-18 17:35:06 -0500 | Rating Details | |
2023-05-18 17:34:56 -0500 | Rating Details | |
2023-05-18 17:25:23 -0500 | Rating Details | |
2023-05-18 17:12:37 -0500 | Rating Details | |
2023-05-18 17:09:28 -0500 | Rating Details | |
2023-05-18 17:07:06 -0500 | Rating Details | |
2023-05-18 17:02:45 -0500 | Rating Details | |
2023-05-18 16:59:08 -0500 | Rating Details | |
2023-05-18 11:07:10 -0500 | Rating Details | |
2023-05-18 10:12:13 -0500 | Rating Details | |
2023-05-18 09:22:31 -0500 | Rating Details | |
2023-05-18 09:13:38 -0500 | Rating Details | |
2023-05-18 08:36:44 -0500 | Rating Details | |
2023-05-18 08:29:00 -0500 | Rating Details | |
2023-05-18 08:26:04 -0500 | Rating Details | |
2023-05-18 08:07:23 -0500 | Rating Details | |
2023-05-18 08:04:05 -0500 | Rating Details | |
2023-05-18 07:57:38 -0500 | Rating Details | |
2023-05-19 09:00:05 -0500 | Rating Details | |
2023-05-18 23:29:38 -0500 | Rating Details | |
2023-05-18 20:03:40 -0500 | Rating Details | |
2023-05-18 19:50:51 -0500 | Rating Details | |
2023-05-18 19:40:41 -0500 | Rating Details | |
2023-05-18 08:04:05 -0500 | Rating Details | |
2023-05-18 17:12:37 -0500 | Rating Details | |
2023-05-18 18:10:17 -0500 | Rating Details | |
2023-05-18 19:03:51 -0500 | Rating Details | |
2023-05-18 17:07:06 -0500 | Rating Details | |
2023-05-18 19:50:51 -0500 | Rating Details | |
2023-05-18 11:07:10 -0500 | Rating Details | |
2023-05-18 18:55:55 -0500 | Rating Details | |
2023-05-18 17:09:28 -0500 | Rating Details | |
2023-05-18 17:48:09 -0500 | Rating Details | |
2023-05-18 17:35:06 -0500 | Rating Details | |
2023-05-18 18:18:09 -0500 | Rating Details | |
2023-05-18 17:02:45 -0500 | Rating Details | |
2023-05-18 16:59:08 -0500 | Rating Details | |
2023-05-18 08:07:23 -0500 | Rating Details | |
2023-05-18 18:15:27 -0500 | Rating Details | |
2023-05-18 08:29:00 -0500 | Rating Details | |
2023-05-18 18:40:27 -0500 | Rating Details | |
2023-05-18 09:22:31 -0500 | Rating Details | |
2023-05-18 17:34:56 -0500 | Rating Details | |
2023-05-18 17:25:23 -0500 | Rating Details | |
2023-05-18 07:57:38 -0500 | Rating Details | |
2023-05-18 18:49:15 -0500 | Rating Details | |
2023-05-18 18:19:40 -0500 | Rating Details | |
2023-05-18 18:27:18 -0500 | Rating Details | |
2023-05-18 19:15:13 -0500 | Rating Details | |
2023-05-18 19:23:57 -0500 | Rating Details | |
2023-05-18 18:32:59 -0500 | Rating Details | |
2023-05-18 18:10:49 -0500 | Rating Details | |
2023-05-18 18:25:21 -0500 | Rating Details | |
2023-05-18 09:13:38 -0500 | Rating Details | |
2023-05-18 18:17:57 -0500 | Rating Details | |
2023-05-18 23:29:38 -0500 | Rating Details | |
2023-05-18 10:12:13 -0500 | Rating Details | |
2023-05-19 09:00:05 -0500 | Rating Details | |
2023-05-18 19:40:41 -0500 | Rating Details | |
2023-05-18 18:33:24 -0500 | Rating Details | |
2023-05-18 18:24:06 -0500 | Rating Details | |
2023-05-18 18:30:08 -0500 | Rating Details | |
2023-05-18 08:26:04 -0500 | Rating Details | |
2023-05-18 18:55:41 -0500 | Rating Details | |
2023-05-18 18:30:57 -0500 | Rating Details | |
2023-05-18 18:19:31 -0500 | Rating Details | |
2023-05-18 20:03:40 -0500 | Rating Details | |
2023-05-18 08:36:44 -0500 | Rating Details |